Search Results - "Kuz’minov, A. E."

Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer by Lyubimova, N. V., Kuz’minov, A. E., Markovich, A. A., Lebedeva, A. V., Timofeev, Yu. S., Stilidi, I. S., Kushlinskii, N. E.

“…The serum levels of pro-gastrin-releasing peptide (proGRP), neuron-specific enolase (NSE), and chromogranin A (CgA) were studied in 69 patients with small cell…”
Get full text

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment by Kuzminov, A. E., Borisova, T. N., Breder, V. V., Reutova, E. V., Barbolina, T. D., Laktionov, K. K.

“…Introduction. In modern recommendations for the treatment of localized small cell lung cancer (SCLC), preference is given to socalled «early» chemoradiotherapy…”
Get full text

The first experience of immunotherapy application of ipilimumab in combination with chemotherapy of small-cell lung cancer in the Russian population. Analysis of the combined data of two centers, participating in the multicenter randomized phase III study СА 184-156 by Kuzminov, A E, Gorbunova, V A, Poddubskaya, E V, Bagrova, S G, Baranova, M P, Laktionov, K K

“…Introduction. Patients with advanced small cell lung cancer (SCLC) have an extremely poor prognosis on the background of standard chemotherapy combination of…”
Get full text

Potential for use sunitinib in pancreatic neuroendocrine tumors by Markovich, A. A., Kuznetsova, A. A., Gorbunova, V. A., Orel, N. F., Odintsova, A. S., Emelyanova, G. S., Kuzminov, A. E.

“…The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib…”
Get full text

PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT by Emelianova, G. S., Orel, N. F., Gorbunova, V. A., Kolomeytseva, A. A., Kuznetsova, A. A., Kuzminov, A. E., Fedenko, A. A.

“…Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options…”
Get full text

Predictors of the immunochemotherapy effectiveness of atezolizumab in combination with etoposide and carboplatin in patients with advanced small cell lung cancer by Kuzminov, A. E., Barbolina, T. D., Reutova, E. V., Yudin, D. I., Breder, V. V., Laktionov, K. K.

“…Introduction. Lung cancer remains the leading cause of cancer-related deaths worldwide. For the first time in 30 years, the randomized clinical studies…”
Get full text

Atezolizumab and bevacizumab in the treatment of advanced hepatocellular cancer with adverse factors and tumor thrombosis by Dzhanyan, I. A., Khagazheeva, M. N., Breder, V. V., Yudin, D. I., Pogrebnyakov, I. V., Kuzminov, A. E., Antonova, E. Yu, Starostin, N. M.

“…Introduction . Hepatocellular cancer in the Russian Federation remains an important problem due to the high one-year mortality rate, which is 61.9%. Рercentage…”
Get full text

Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer by Kuz'minov, A E, Gorbunova, V A, Naskhletashvili, D R

“…The paper discusses the results of phase II clinical trials of chemotherapy regimens using newly-developed cytostatics for disseminated small cell lung cancer…”
Get more information

Sovremennye napravleniya lecheniyaneyroendokrinnykh opukholey by V A Gorbunova, N F Orel, A E Kuz'minov

Get full text

Primenenie Aranozy pri neyroendokrinnykh opukholyakh by V A Gorbunova, N F Orel, A E Kuz'minov

“…Нейроэндокринные опухоли (НЭО) – достаточно редкие опухоли (частота составляет от 2 до 5 случаев на 100 тыс. населения), возникающие из клеток диффузной…”
Get full text

Interferon α (IFN-α) vs. the combination IFN-α and octreotide LAR in the treatment of patients with well differentiated neuroendocrine tumors (NET) of various localizations by G S Yemelyanova, A E Kuzminov, N F Orel, A A Markovich, A A Kuznetsova, V A Gorbunova

“…It is still unknown whether the combination of IFN-α with octreotide has benefit compared with IFN-α alone. We compared efficacy and toxicyty of IFN-α and…”
Get full text

Experience of use of everolimus and long-acting somatostatin analogues combination in highly differentiated (G1-G2) neuroendocrine tumors by A A Markovich, A E Kuzminov, N F Orel, A S Odintsova, G S Emelyanova, V A Gorbunova

“…Everolimus is the targeted drug approved for the treatment of neuroendocrine tumors (NET). Efficacy of everolimus in combination with octreotide-depo has been…”
Get full text

Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of application in case of unsatisfactory tolerability of octreotide by Emelyanova, G.S., Kuzminov, A.E., Orel, N.F., Odintsova, A.S., Markovich, A.A., Kuznetsova, A.A., Gorbunova, V.A.

“…Somatostatin analogs plays a key role in the treatment of disseminated well-differentiated functioning and nonfunctioning neuroendocrine tumors (NET). Its…”
Get full text

Thermostable interference oxide coatings for active elements of IR lasers by Zagoruiko Yu. A., Fedorenko O. A., Kovalenko N. O., Kuzminov E. A., Mateychenko P. V.

“…Strong thermostable oxide interference coatings transparent in the visible and IR spectral regions are obtained on the surface of active elements of…”
Get full text

ENDOVASCULAR TREATMENT OF LOCALLY-ADVANCED RECTAL CARCINOMA CONSIDERING SPECIFIC FEATURES OF BLOOD SUPPLY OF RECTUM (THE REVIEW OF LITERATURE AND OWN OBSERVATIONS) by V. V. Breder, V. A. Gorbunova, N. F. Orel, K. V. Orlova, A. E. Kuzminov, T. A. Борисова, Yu. V. Bisovskaya, I. N. Gagarin, N. N. Mazurenko, V. V. Mochalnikova, E. N. Kholyavka

“…The review literature regarding endovascular interventions for rectal cancer treatment is presented. The results of treatment of loco-regional rectal carcinoma…”
Get full text